Cannon Global Investment Management LLC Acquires Shares of 47,500 aTyr Pharma, Inc. (NASDAQ:ATYR)

Cannon Global Investment Management LLC purchased a new stake in aTyr Pharma, Inc. (NASDAQ:ATYR - Free Report) in the first quarter, according to its most recent filing with the SEC. The fund purchased 47,500 shares of the company's stock, valued at approximately $143,000. Cannon Global Investment Management LLC owned about 0.05% of aTyr Pharma at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of ATYR. Charles Schwab Investment Management Inc. bought a new stake in aTyr Pharma during the fourth quarter worth approximately $144,000. Victory Capital Management Inc. acquired a new position in aTyr Pharma during the fourth quarter worth $37,000. Raymond James Financial Inc. acquired a new position in shares of aTyr Pharma during the 4th quarter valued at about $39,000. Farther Finance Advisors LLC bought a new position in shares of aTyr Pharma in the fourth quarter valued at approximately $88,000. Finally, American Century Companies Inc. acquired a new position in aTyr Pharma during the 4th quarter worth $319,000. 61.72% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. HC Wainwright reissued a "buy" rating and issued a $35.00 price target on shares of aTyr Pharma in a report on Wednesday, June 4th. Wells Fargo & Company boosted their price target on shares of aTyr Pharma from $17.00 to $25.00 and gave the stock an "overweight" rating in a research note on Friday, June 20th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $20.20.

aTyr Pharma Stock Down 0.5%

ATYR stock traded down $0.03 during midday trading on Friday, hitting $5.25. The company's stock had a trading volume of 2,380,688 shares, compared to its average volume of 1,236,362. The company's fifty day moving average price is $4.34 and its 200 day moving average price is $3.78. aTyr Pharma, Inc. has a twelve month low of $1.48 and a twelve month high of $5.98. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.79 and a quick ratio of 7.79. The stock has a market capitalization of $467.63 million, a P/E ratio of -6.49 and a beta of 0.89.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.02. As a group, equities research analysts predict that aTyr Pharma, Inc. will post -0.91 EPS for the current year.

About aTyr Pharma

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.